Skip to main content
CHRS logo

CHRS · Coherus Oncology, Inc. · Documents

Track CHRS — free
$0.37 -0.02 (-4.47%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$57.15M
Shares
154.54M
Volume · Nov 20 2.52M Avg daily vol (3M) 1.8M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $42.17M up 59.8% 10-K filed Mar 9, 2026 Quarterly report FY2026 Q3 Revenue $14.27M up 23.4% 10-Q filed Nov 9, 2026 Latest results Esophageal cancer prioritized as headcount cut ~30% 8-K filed Nov 9, 2026 Earnings call Q3 2026 earnings call Held Nov 9, 2026
2026
Nov 10
Investor event
Prioritizes Esophageal Cancer After 89% First-Line Response; 30% Headcount Cut

Coherus Oncology is prioritizing esophageal cancer after eight out of nine evaluable first-line esophageal squamous cell patients responded, an 89% ORR. The company is cutting headcount by 30%, primarily on the non-commercial side. It plans to meet FDA early in 2027 on the recommended phase two dose.

4 source passages
In first-line esophageal squamous cell, we saw eight out of nine of the evaluable patients responded, including one complete response So that equated to an 89% ORR. We are putting in place a 30% headcount reduction that's primarily across the non-commercial side of the business we are putting together a meeting request right now to go to FDA early in 2027 to get alignment on the recommended phase two dose. Open the document at this passage
Nov 9
Earnings call
Esophageal focus drives 30% headcount cut and cost savings

Coherus Oncology, Inc. is prioritizing esophageal cancer, cutting headcount approximately 30% from about 140 to 100 FTEs and expecting $6 to $7 million per quarter in savings; cash runway remains less than 12 months.

5 source passages
Welcome to the Q3 2026 Coherest Oncology Inc. Earnings Conference Call. The emerging data from this very systematic clinical investigation demonstrated that esophageal cancer comprises a best-in-disease opportunity across first and second lines of therapy. Once implemented, we expect a sustainable reduction in recurring costs of $6 to $7 million per quarter on average and expect to achieve most of this rate of savings within two quarters. These savings will come primarily from an approximately 30% reduction in headcount from about 140 to 100 FTEs, which will take place this month. Without considering the potential benefit of the cost reductions, the payment of the milestone, or proceeds from ex-US deals, our cash runway is less than 12 months from the date of the 10-Q we filed today. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Going-concern doubt persists with $83.6 million in liquidity

Coherus Oncology reported $83.6 million in cash and marketable securities as of September 30, 2026. Management concluded substantial doubt about the company's ability to continue as a going concern remained, citing expected operating losses, negative cash flows and additional funding needs.

Revenue $14.27M ▲ 23.4% Net loss $39.33M Diluted EPS -$0.25
Read from the MD&A section
2 source passages
As of September 30, 2026, we had cash, cash equivalents and marketable securities that totaled $83.6 million and an accumulated deficit of $1.5 billion. After considering these plans and the guidance within ASC 205-40, we concluded that substantial doubt about our ability to continue as a going concern had not been alleviated for the one-year period following the issuance of these condensed consolidated financial statements. Open the document at this passage
Nov 9
Current report 8-K
Esophageal cancer prioritized as headcount cut ~30%

Coherus Oncology prioritized tagmokitug/toripalimab development for esophageal cancer, reduced headcount by ~30%, and reported Q3 2026 LOQTORZI net revenue of $14.0 million. Q3 net loss from continuing operations was $38.9 million, or $(0.25) per diluted share.

Financial results
4 source passages
Right-sizing reduces headcount by ~30%, aligning organization with forward-focused needs As part of the strategic prioritization plan, Coherus will focus near-term tagmokitug development on esophageal cancer and deprioritize the other tagmokitug-toripalimab cohorts presented during our October 28, 2026, data release. LOQTORZI revenue for Q3 2026 was $14.0 million, a 25% increase over $11.2 million in Q3 2025, and a 3% increase versus $13.6 million in Q2 2026. Net loss from continuing operations for the third quarter of 2026 was $38.9 million, or $(0.25) per share on a diluted basis, compared to $44.5 million, or $(0.38) per share on a diluted basis, for the same period in 2025. Open the document at this passage
Oct 29
Current report 8-K Events of Oct 28
Tagmokitug Shows 75% Confirmed ORR in First-Line Esophageal Cancer Interim Data

Coherus reported interim TREGCHECK data for tagmokitug with toripalimab, with or without chemotherapy, in solid tumors. In evaluable front-line esophageal squamous cell carcinoma patients, the confirmed overall response rate was 75% irrespective of PD-L1 status and 100% in PD-L1 positive patients as of October 14, 2026. The company plans to expand enrollment in first-line and second-line ESCC cohorts.

Regulation FD disclosure, Other events
2 source passages
In evaluable front-line esophageal squamous cell carcinoma ("ESCC") patients, tagmokitug in combination with toripalimab and chemotherapy demonstrated a confirmed overall response rate ("cORR") of 75% irrespective of PD-L1 status, and a cORR of 100% in PD-L1 positive patients as of October 14, 2026. Based on the interim findings, the Company plans to expand enrollment in first-line and second-line ESCC Open the document at this passage
Aug 28
Current report 8-K
Other events AI summary on its way
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $14.31M ▲ 39.5% Net loss $20.63M Diluted EPS -$0.13
May 11
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $12.31M ▲ 62.0% Net loss $38.33M Diluted EPS -$0.28
Apr 20
Proxy statement DEF 14A Meeting May 27, 2026
Proxy statement AI summary on its way
Apr 9
Proxy statement PRE 14A Meeting May 27, 2026
Proxy statement AI summary on its way
Mar 9
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $42.17M ▲ 59.8% Net income $168.02M ▲ 489.4% Diluted EPS $1.43 ▲ 472.0%
Feb 17
Current report 8-K Events of Feb 12
Other events AI summary on its way
Feb 4
Current report 8-K
Other events AI summary on its way
Jan 23
Current report 8-K
Other events AI summary on its way
2025
Showing 1–50 of 205 documents
Key facts CIK 1512762 CUSIP 19249H103 13F (30d) 150 filings 120 filers Visit website Investor relations